{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-138563","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.593062+00:00","generated_at":"2026-05-29T01:44:10.353477+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106","bullets":["Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.","Across 6 solid tumor types (n=31), PYX-201 achieved 26% ORR with dose-dependent responses in taxane-pretreated patients.","PYX-106 program suspended; Phase 1 monotherapy enrolled 45 patients, was safe and well-tolerated.","Current cash position expected to fund PYX-201 monotherapy and combination trials into 2H 2026.","Monotherapy and pembrolizumab combination trials for PYX-201 expected to start dosing in early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-138563","json":"https://secwatch.observer/filing/0000950170-24-138563.json","markdown":"https://secwatch.observer/filing/0000950170-24-138563.md","text":"https://secwatch.observer/filing/0000950170-24-138563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024138563/0000950170-24-138563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024138563/pyxs-20241219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:44:10.353477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}